New approach aims to wipe out hidden cancer cells after lung surgery

NCT ID NCT04367311

Ongoing Disease control Sponsor: Nasser Hanna Source: ClinicalTrials.gov ↗

Summary

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy after lung cancer surgery can better prevent the cancer from returning. It focuses on patients who have signs of remaining cancer cells in their blood after surgery, which indicates high risk of recurrence. Researchers will track whether this combination treatment can clear these cancer markers from the blood and keep patients cancer-free longer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
New York University Clinical Cancer Center

New York, New York, 10016, United States
Northwestern University Feinberg School of Medicine

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Penn State Cancer Institute

Hershey, Pennsylvania, 17033, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Summit Health

Berkeley Heights, New Jersey, 07922, United States
University of Virginia Health System

Charlottesville, Virginia, 22908, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

Conditions

Explore the condition pages connected to this study.

LUNG CANCER NSCLC